Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Pharma tends to treat quality and innovation as competing priorities when they’re not. While the industry may understand that the two can facilitate each other, what is less understood is how to achieve both reliably. Quality-by-Design is the mechanism that makes both possible at the same time.
What Is Quality-by-Design in Pharma Development?
Quality-by-Design (QbD) is a structured, science-based approach to pharmaceutical development in which quality is designed into the product and process development from the outset rather than tested into the final product.
Researchers at IQS-Universitat Ramon Llull and Esade used bibliometric mapping and content analysis across the QbD literature to produce the first management-lens framework for how QbD functions as an innovation strategy in the pharmaceutical sector.
QbD was formalised for the pharmaceutical sector through three International Council for Harmonisation (ICH) guidelines: ICH Q8[R2] (Pharmaceutical Development), ICH Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System).
The ICH Q8(R2) guideline introduced the concept of a design space, a defined range of process parameters within which manufacturers can operate without triggering a regulatory submission for each change.
The risk assessment tools for identifying critical quality attributes (CQAs) and critical process parameters (CPPs) are defined in ICH Q9, and these are embedded within a lifecycle quality system by ICH Q10.
When fully implemented, QbD becomes part of a development programme that anticipates failure modes rather than discovering them during commercial manufacturing.
This makes QbD more than a compliance exercise and, rather, a strategic innovation approach that shapes how pharma companies generate new knowledge, build regulatory confidence, and create competitive advantage.
QbD remains underexplored in pharma R&D and manufacturing supply chain management and has primarily been limited to chemistry, pharmacy, and process engineering.
However, when applied through the lens of innovation management as part of a quality ecosystem, QbD can offer the most innovative value in pharma.
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.
Three Forces Driving QbD Adoption in Pharma
There are three simultaneous forces that are currently interacting to drive QbD adoption across the pharmaceutical sector:
Regulatory push
The U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA) have actively encouraged QbD adoption since the early 2000s.
FDA pilot programmes for QbD submissions ran from 2005, and regulators now expect sponsors to demonstrate process understanding rather than simply present end-product specifications.
The FDA's Quality Resources explicitly support design space and real-time release testing as QbD mechanisms.
Science push
Advances in process analytical technology (PAT), Design of Experiments (DoE), multivariate data analysis, and computational modelling have made QbD achievable at scale.
Continuous manufacturing, which QbD enables, is now commercially viable for small molecules and is being extended to biologics.
Market pull
Competitive pressure and the commercial cost of late-stage manufacturing failures have made proactive quality design an economic imperative, not just a regulatory preference.
Market pull and the two push forces are not operating in sequence but rather simultaneously, reinforcing each other within what is called a 'QbD innovation ecosystem' involving regulators, standard-setting bodies, academic researchers, biotechnology suppliers, and pharma manufacturers.
QbD Innovation Outcomes in Pharma
The distinction between the types of QbD innovations is important for R&D leaders to understand.
QbD is most strongly associated with continuous improvement, creating incremental, iterative gains in process performance, yield, and product consistency as the most reliable innovation outputs.
Radical innovation, defined as genuinely novel therapeutic modalities or platform technologies, is a secondary and indirect outcome. QbD enables radical innovation by freeing R&D resources from quality remediation work and by generating the deep process knowledge that underpins novel platform development.
Research on QbD in pharma has expanded significantly since 2010, with the move to experimental formulation, industrial-scale case studies, continuous manufacturing, nanoformulations, and biologics.
Such research focuses on how QbD functions differently across innovation types, how ecosystem actors interact in QbD adoption, and how QbD principles extend to advanced therapy medicinal products (ATMPs).
Existing research shows that organisations that implement QbD only at the level of a single product or process, rather than as a cross-functional quality culture, consistently capture less of the innovation benefit.
The ecosystem framing matters because the value of QbD increases when it is embedded in supplier relationships, analytical development, regulatory strategy, and commercial manufacturing simultaneously.
What QbD Means for Pharmaceutical R&D Leaders
Several proven insights about QbD are worth acting on for pharma R&D leaders.
First, if your organisation treats QbD primarily as a regulatory compliance mechanism, you are leaving significant competitive advantage unrealised. The design space that QbD establishes goes beyond a regulatory document and is proprietary process knowledge that reduces development risk in future programmes.
Secondly, the three-force model has a practical implication for timing. Regulatory push is now strong enough in both the U.S. and EU that QbD adoption is effectively expected in approval submissions.
The science push is accelerating as PAT, continuous manufacturing, and AI-driven process modelling become more accessible. At the same time, the market pull is intensifying as late-stage manufacturing failures remain costly and visible.
Finally, there is a clear management research agenda reflecting a genuine gap where pharmaceutical organisations frequently implement QbD technically without the organisational structures that allow QbD to function as an innovation platform rather than a compliance task.
Such organisational structures needed for effective QbD implementation include cross-functional steering, knowledge management systems, and supply chain integration, amongst others.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Conclusion: Ensure Quality and Accelerate Pharma Innovation with Design
There is now the strong regulatory and scientific push and market pull for pharmaceutical innovation through Quality-by-Design.
QbD directly enables continuous improvement in process performance and indirectly supports radical innovation by freeing R&D capacity and deepening process knowledge.
Organisations implementing QbD as an organisation-wide quality culture, rather than a product-level compliance activity, substantially capture more of its potential innovation value.
At Pharmatica, we track how regulatory frameworks and manufacturing innovation interact to shape pharmaceutical R&D strategy. Our analysis connects the evidence base from management research, regulatory guidance, and industry practice to give R&D and manufacturing leaders the intelligence they need to make informed strategic decisions.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is Quality-by-Design in pharmaceutical development?
Quality-by-Design (QbD) in pharmaceutical development is a systematic, science-based approach to pharmaceutical development in which product quality is built into the design of the product and manufacturing process from the outset. It is formalised through ICH guidelines Q8, Q9, and Q10.
QbD is supported by the FDA and EMA as the preferred approach to pharmaceutical development submissions.
How does QbD relate to innovation in pharma?
QbD relates to innovation in pharma by enabling continuous improvement directly. It can also support radical innovation indirectly through freeing R&D resources from quality remediation and deepening process knowledge.
QbD functions as an ecosystem-based innovation strategy shaped by regulatory push, science push, and market pull simultaneously.
What are the ICH guidelines for Quality-by-Design?
The three core ICH guidelines for QbD are Q8 (Pharmaceutical Development), which introduced the design space concept; Q9 (Quality Risk Management), which formalised risk assessment tools; and Q10 (Pharmaceutical Quality System), which embedded these in a lifecycle quality framework. ICH Q14, finalised in 2023, extended QbD principles to analytical procedure development.
Why is QbD important for biologics and advanced therapies?
QbD is important for biologics and advanced therapies, as these are both more complex than small molecules and, therefore, make end-product testing a less reliable quality assurance mechanism.
QbD's emphasis on process understanding, design spaces, and continuous monitoring is particularly valuable for these modalities, where manufacturing variability has direct implications for clinical safety and efficacy. Recent literature has extended QbD frameworks to continuous biomanufacturing and nanoformulations.
What is the difference between QbD and traditional pharmaceutical development?
The difference between QbD and traditional pharmaceutical development is while the latter relies on fixed specifications and end-product testing to confirm quality, QbD builds quality in from the outset by defining critical quality attributes, establishing design spaces for process parameters, and implementing continuous monitoring.
The result of QbD in pharma development is greater manufacturing flexibility, stronger regulatory confidence, and earlier identification of potential failure modes.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)